Evaluation of Antibody Response to SARS-CoV-2 mRNA-1273 Vaccination in Patients With Cancer in Florida

Article Immunology

SARS-CoV-2 Period Seroprevalence and Related Factors, Hillsborough County, Florida, USA, October 2020-March 2021

Anna R. Giuliano et al.

Summary: This study estimated the SARS-CoV-2 seroprevalence among residents of Hillsborough County, Florida, and found that factors related to social distancing were associated with infection rate, regardless of the time since infection.

EMERGING INFECTIOUS DISEASES (2022)

添加到收藏夹

Article Hematology

Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines

Christopher Pleyer et al.

Summary: Treatment with BTK inhibitors resulted in a lower immune response rate to the HepB-CpG vaccine, but did not significantly affect the response rate to the RZV vaccine in CLL patients.

BLOOD (2021)

添加到收藏夹

Letter Medicine, General & Internal

Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine

Kai Wu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Letter Medicine, General & Internal

Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants

Laith J. Abu-Raddad et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Letter Medicine, General & Internal

Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19

Nicole Doria-Rose et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Oncology

Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium

P. Grivas et al.

Summary: This study analyzed clinical factors and laboratory measurements of cancer patients with COVID-19, finding that factors such as age, sex, comorbidities, cancer type, and laboratory results were associated with COVID-19 severity. Patients diagnosed early in the pandemic had worse outcomes, and specific anticancer therapies may increase 30-day all-cause mortality. More research is needed to confirm these findings and caution may be needed in using certain anticancer treatments.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Seroconversion rates following COVID-19 vaccination among patients with cancer

Astha Thakkar et al.

Summary: Most cancer patients show high seroconversion rates after receiving COVID-19 vaccines, but those with hematologic malignancies, especially after highly immunosuppressive therapies, exhibit lower conversion rates. Patients on immune checkpoint inhibitor therapy or hormonal therapy display high conversion rates.

CANCER CELL (2021)

添加到收藏夹

Letter Oncology

Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies

Lee M. Greenberger et al.

CANCER CELL (2021)

添加到收藏夹

Article Multidisciplinary Sciences

COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants

Pinja Jalkanen et al.

Summary: The study shows that the second dose of the BNT162b2 vaccine can induce cross-neutralization to some extent of SARS-CoV-2 variants, providing partial protection. Despite the reduced neutralization effect on the B.1.351 variant, the majority of vaccinees still have some level of protection.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Article Oncology

Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer

Amir Massarweh et al.

Summary: The study showed that 90% of patients with cancer undergoing treatment had an adequate antibody response to the BNT162b2 vaccine, although their antibody titers were significantly lower than those of healthy controls. Further research is needed to explore the clinical relevance and durability of these lower titers.

JAMA ONCOLOGY (2021)

添加到收藏夹

Article Immunology

Suboptimal Response to Coronavirus Disease 2019 Messenger RNA Vaccines in Patients With Hematologic Malignancies: A Need for Vigilance in the Postmasking Era

Mounzer E. Agha et al.

Summary: It was found that about half of patients with hematological malignancies did not produce sufficient immune response after receiving two doses of vaccine, with B-cell chronic lymphocytic leukemia patients at a higher risk. Therefore, these patients need to continue taking protective measures. More research is needed to understand revaccination, boosters, and immune protection correlates.

OPEN FORUM INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

A serological assay to detect SARS-CoV-2 seroconversion in humans

Fatima Amanat et al.

NATURE MEDICINE (2020)

添加到收藏夹

Article Medicine, General & Internal

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

E. J. Anderson et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Evaluation of Antibody Response to SARS-CoV-2 mRNA-1273 Vaccination in Patients With Cancer in Florida

相关参考文献

导出引文

分享论文